Cargando…

Cardiovascular Diseases in COPD: From Diagnosis and Prevalence to Therapy

Chronic obstructive pulmonary disease (COPD) is considered one of the leading causes of mortality. Cardiovascular comorbidities are diagnosed often in COPD patients, not only because of the common risk factors these two diseases share, but also because of the systemic inflammation which characterize...

Descripción completa

Detalles Bibliográficos
Autores principales: Papaporfyriou, Anastasia, Bartziokas, Konstantinos, Gompelmann, Daniela, Idzko, Marco, Fouka, Evangelia, Zaneli, Stavrina, Bakakos, Petros, Loukides, Stelios, Papaioannou, Andriana I.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10301030/
https://www.ncbi.nlm.nih.gov/pubmed/37374082
http://dx.doi.org/10.3390/life13061299
_version_ 1785064716044861440
author Papaporfyriou, Anastasia
Bartziokas, Konstantinos
Gompelmann, Daniela
Idzko, Marco
Fouka, Evangelia
Zaneli, Stavrina
Bakakos, Petros
Loukides, Stelios
Papaioannou, Andriana I.
author_facet Papaporfyriou, Anastasia
Bartziokas, Konstantinos
Gompelmann, Daniela
Idzko, Marco
Fouka, Evangelia
Zaneli, Stavrina
Bakakos, Petros
Loukides, Stelios
Papaioannou, Andriana I.
author_sort Papaporfyriou, Anastasia
collection PubMed
description Chronic obstructive pulmonary disease (COPD) is considered one of the leading causes of mortality. Cardiovascular comorbidities are diagnosed often in COPD patients, not only because of the common risk factors these two diseases share, but also because of the systemic inflammation which characterizes COPD and has deleterious effects in the cardiovascular system. The comorbid cardiovascular diseases in COPD result in several difficulties in the holistic treatment of these patients and affect outcomes such as morbidity and mortality. Several studies have reported that mortality from cardiovascular causes is common among COPD patients, while the risk for acute cardiovascular events increases during COPD exacerbations and remains high for a long time even after recovery. In this review, we focus on the prevalence of cardiovascular comorbidities in COPD patients, presenting the evidence regarding the interaction of the pathophysiological pathways which characterize each disease. Furthermore, we summarize information regarding the effects of cardiovascular treatment on COPD outcomes and vice versa. Finally, we present the current evidence regarding the impact of cardiovascular comorbidities on exacerbations, quality of life and survival of COPD patients.
format Online
Article
Text
id pubmed-10301030
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-103010302023-06-29 Cardiovascular Diseases in COPD: From Diagnosis and Prevalence to Therapy Papaporfyriou, Anastasia Bartziokas, Konstantinos Gompelmann, Daniela Idzko, Marco Fouka, Evangelia Zaneli, Stavrina Bakakos, Petros Loukides, Stelios Papaioannou, Andriana I. Life (Basel) Review Chronic obstructive pulmonary disease (COPD) is considered one of the leading causes of mortality. Cardiovascular comorbidities are diagnosed often in COPD patients, not only because of the common risk factors these two diseases share, but also because of the systemic inflammation which characterizes COPD and has deleterious effects in the cardiovascular system. The comorbid cardiovascular diseases in COPD result in several difficulties in the holistic treatment of these patients and affect outcomes such as morbidity and mortality. Several studies have reported that mortality from cardiovascular causes is common among COPD patients, while the risk for acute cardiovascular events increases during COPD exacerbations and remains high for a long time even after recovery. In this review, we focus on the prevalence of cardiovascular comorbidities in COPD patients, presenting the evidence regarding the interaction of the pathophysiological pathways which characterize each disease. Furthermore, we summarize information regarding the effects of cardiovascular treatment on COPD outcomes and vice versa. Finally, we present the current evidence regarding the impact of cardiovascular comorbidities on exacerbations, quality of life and survival of COPD patients. MDPI 2023-05-31 /pmc/articles/PMC10301030/ /pubmed/37374082 http://dx.doi.org/10.3390/life13061299 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Papaporfyriou, Anastasia
Bartziokas, Konstantinos
Gompelmann, Daniela
Idzko, Marco
Fouka, Evangelia
Zaneli, Stavrina
Bakakos, Petros
Loukides, Stelios
Papaioannou, Andriana I.
Cardiovascular Diseases in COPD: From Diagnosis and Prevalence to Therapy
title Cardiovascular Diseases in COPD: From Diagnosis and Prevalence to Therapy
title_full Cardiovascular Diseases in COPD: From Diagnosis and Prevalence to Therapy
title_fullStr Cardiovascular Diseases in COPD: From Diagnosis and Prevalence to Therapy
title_full_unstemmed Cardiovascular Diseases in COPD: From Diagnosis and Prevalence to Therapy
title_short Cardiovascular Diseases in COPD: From Diagnosis and Prevalence to Therapy
title_sort cardiovascular diseases in copd: from diagnosis and prevalence to therapy
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10301030/
https://www.ncbi.nlm.nih.gov/pubmed/37374082
http://dx.doi.org/10.3390/life13061299
work_keys_str_mv AT papaporfyriouanastasia cardiovasculardiseasesincopdfromdiagnosisandprevalencetotherapy
AT bartziokaskonstantinos cardiovasculardiseasesincopdfromdiagnosisandprevalencetotherapy
AT gompelmanndaniela cardiovasculardiseasesincopdfromdiagnosisandprevalencetotherapy
AT idzkomarco cardiovasculardiseasesincopdfromdiagnosisandprevalencetotherapy
AT foukaevangelia cardiovasculardiseasesincopdfromdiagnosisandprevalencetotherapy
AT zanelistavrina cardiovasculardiseasesincopdfromdiagnosisandprevalencetotherapy
AT bakakospetros cardiovasculardiseasesincopdfromdiagnosisandprevalencetotherapy
AT loukidesstelios cardiovasculardiseasesincopdfromdiagnosisandprevalencetotherapy
AT papaioannouandrianai cardiovasculardiseasesincopdfromdiagnosisandprevalencetotherapy